Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870037 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer
A Phase 1 study, sponsored by Urovant Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01870037: Completed Phase 1 study, sponsored by Urovant Sciences.
NCT01870037 is a Phase 1 study that has completed, run by Urovant Sciences. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01870037, a Phase 1 study, has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of a single treatment of hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections. Two dose levels (16000 µg and 24000 µg; 20 or 30 bladder wall injections, respectively) in females with moderate Overactive Bladder/Detrusor overactivity (OAB/DO) of ≥6 months duration will be evaluated. In each dose level, 6 participants will receive hMaxi-K and 3 will receive placebo.
Interventions
- DRUG Placebo (PBS-20% sucrose)
- DRUG hMaxi-K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-01 |
| Est. Completion | 2018-02-17 |
| Phase | Phase 1 |
What the finished NCT01870037 record still lists
NCT01870037 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo (PBS-20% sucrose) is the first listed.
NCT01870037 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01870037 about?
NCT01870037 is a clinical study titled "Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer". The primary objective of this study is to evaluate the safety of a single treatment of hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections. Two dose levels (16000 µg and 24000 µg; 20 or 30 bladder wall injections, respectively) in females with moderate Overac...
What is the current status of trial NCT01870037?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2013-01. Estimated completion is 2018-02-17.
What interventions are being tested in trial NCT01870037?
The interventions under investigation include: Placebo (PBS-20% sucrose) (DRUG), hMaxi-K (DRUG).
Who is sponsoring clinical trial NCT01870037?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01870037's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia